AGM 2024 - QUESTIONS, page-45

Thanks Denial.

I will be in touch with Paradigm about the trial and some other questions I have.

From my read the initial phase 3 (oa 11) did not meet primary end points but their extension study oa o7 did meet its primary "objective" and did show structural benefit over placebo..

It seems we are obviously way more advanced and our target of KL 3 and 4 is different to where their drug shows most benefit KL2.
I assume they would also need to start a whole new FDA aproved phase 3. So it kooks like we are good...

I also noticed another early trial for hand and finger joint OA with another repurposed drug called Talarozole. Different specific indication and early days but worth noting

https://www.medicalnewstoday.com/articles/new-repurposed-drug-talarozole-hand-osteoarthritis